-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Triple-negative breast cancer (TNBC) accounts for about 15% of invasive breast cancer.
Triple-negative breast cancer (TNBC) accounts for about 15% of invasive breast cancer.
The study is a randomized phase III study, including II or III TNBC, neoadjuvant chemotherapy with residual lesions greater than or equal to 1 cm, postoperative random allocation to receive platinum-based chemotherapy group and capecitabine group, platinum-based chemotherapy is There is a cycle every 21 days for a total of 4 cycles; while capecitabine is taken for 14 days with 7 days of rest, for a total of 6 cycles.
The study is a randomized phase III study, including II or III TNBC, neoadjuvant chemotherapy with residual lesions greater than or equal to 1 cm, postoperative random allocation to receive platinum-based chemotherapy group and capecitabine group, platinum-based chemotherapy is There is a cycle every 21 days for a total of 4 cycles; while capecitabine is taken for 14 days with 7 days of rest, for a total of 6 cycles.
The study included 410 patients from 2015 to 2021, and 308 patients (78%) were basal TNBC.
Among 308 patients with basal TNBC, the 3-year non-invasive disease progression (iDFS) of platinum therapy and capecitabine therapy were 42% (95% CI, 30 to 53) and 49% (95% CI, 39), respectively.
Different groups of iDFS
Among 88 patients with non-basal TNBC, the 3-year non-invasive disease progression (iDFS) of platinum treatment and capecitabine treatment were 46% (95% CI, 25 to 65) and 69% (95% CI, 45 to 83), the hazard ratio HR=1.
Efficacy evaluation
The grade 3/4 toxicity (mostly anemia and leukopenia) in the platinum-based chemotherapy group was more common than capecitabine, at 26% (95% CI, 20 to 33) vs 15% (95% CI, 10 to 21) ).
The grade 3/4 toxicity (mostly anemia and leukopenia) in the platinum-based chemotherapy group was more common than capecitabine, at 26% (95% CI, 20 to 33) vs 15% (95% CI, 10 to 21) ).
In summary, compared with capecitabine adjuvant chemotherapy, platinum-based adjuvant chemotherapy cannot improve the prognosis of patients with residual basal TNBC after neoadjuvant chemotherapy (NAC).
Original source:
Ingrid A.
Ingrid A.
Mayer; Fengmin Zhao; Carlos L.
Arteaga, et al.
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.
DOI: 10.
1200/ JCO.
21.
00976 Journal of Clinical Oncology.
Published online June 06, 2021.
Leave a message here
